Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer.

Chen KH, Lin LI, Tseng LH, Lin YL, Liau JY, Tsai JH, Liang JT, Lin BR, Cheng AL, Yeh KH.

Oncology. 2019;96(3):156-163. doi: 10.1159/000493387. Epub 2018 Dec 12.

PMID:
30540994
2.

Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.

Lee S, Cho NY, Choi M, Yoo EJ, Kim JH, Kang GH.

Pathol Int. 2008 Feb;58(2):104-13. doi: 10.1111/j.1440-1827.2007.02197.x.

PMID:
18199160
3.

Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women.

Samadder NJ, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, Lynch CF, Anderson KE, French AJ, Haile RW, Potter JD, Slager SL, Smyrk TC, Thibodeau SN, Cerhan JR, Limburg PJ.

Gastroenterology. 2013 Aug;145(2):348-56.e1-2. doi: 10.1053/j.gastro.2013.05.001. Epub 2013 May 7.

4.

CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.

Lee S, Cho NY, Yoo EJ, Kim JH, Kang GH.

Arch Pathol Lab Med. 2008 Oct;132(10):1657-65. doi: 10.1043/1543-2165(2008)132[1657:CIMPIC]2.0.CO;2.

PMID:
18834226
5.

The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.

Min BH, Bae JM, Lee EJ, Yu HS, Kim YH, Chang DK, Kim HC, Park CK, Lee SH, Kim KM, Kang GH.

BMC Cancer. 2011 Aug 10;11:344. doi: 10.1186/1471-2407-11-344.

6.

Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location.

Bae JM, Kim JH, Cho NY, Kim TY, Kang GH.

Br J Cancer. 2013 Aug 20;109(4):1004-12. doi: 10.1038/bjc.2013.430. Epub 2013 Jul 30.

7.

Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.

Murcia O, Juárez M, Rodríguez-Soler M, Hernández-Illán E, Giner-Calabuig M, Alustiza M, Egoavil C, Castillejo A, Alenda C, Barberá V, Mangas-Sanjuan C, Yuste A, Bujanda L, Clofent J, Andreu M, Castells A, Llor X, Zapater P, Jover R.

PLoS One. 2018 Sep 6;13(9):e0203051. doi: 10.1371/journal.pone.0203051. eCollection 2018.

8.
9.

The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.

Dahlin AM, Palmqvist R, Henriksson ML, Jacobsson M, Eklöf V, Rutegård J, Oberg A, Van Guelpen BR.

Clin Cancer Res. 2010 Mar 15;16(6):1845-55. doi: 10.1158/1078-0432.CCR-09-2594. Epub 2010 Mar 2.

10.

Association between molecular subtypes of colorectal cancer and patient survival.

Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, Sinicrope FA, Rosty C, Buchanan DD, Potter JD, Newcomb PA.

Gastroenterology. 2015 Jan;148(1):77-87.e2. doi: 10.1053/j.gastro.2014.09.038. Epub 2014 Sep 30.

11.

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.

Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS.

Gut. 2009 Jan;58(1):90-6. doi: 10.1136/gut.2008.155473. Epub 2008 Oct 2.

12.

Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.

Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, Hazra A, Hunter DJ, Quackenbush J, Spiegelman D, Giovannucci EL, Fuchs CS, Ogino S.

PLoS One. 2008;3(11):e3698. doi: 10.1371/journal.pone.0003698. Epub 2008 Nov 12.

13.

The role of the CpG island methylator phenotype on survival outcome in colon cancer.

Kang KJ, Min BH, Ryu KJ, Kim KM, Chang DK, Kim JJ, Rhee JC, Kim YH.

Gut Liver. 2015 Mar;9(2):202-7. doi: 10.5009/gnl13352.

14.

CpG island methylator phenotype is an independent predictor of survival after curative resection for colorectal cancer: A prospective cohort study.

Kim CH, Huh JW, Kim HR, Kim YJ.

J Gastroenterol Hepatol. 2017 Aug;32(8):1469-1474. doi: 10.1111/jgh.13734.

PMID:
28087988
15.

TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.

Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS.

Hum Pathol. 2007 Apr;38(4):614-20. Epub 2007 Jan 31.

PMID:
17270239
16.

Methylator phenotype in colorectal cancer: A prognostic factor or not?

Gallois C, Laurent-Puig P, Taieb J.

Crit Rev Oncol Hematol. 2016 Mar;99:74-80. doi: 10.1016/j.critrevonc.2015.11.001. Epub 2015 Dec 7. Review.

PMID:
26702883
17.

Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.

Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A.

J Pathol. 2011 Nov;225(3):336-43. doi: 10.1002/path.2879. Epub 2011 Jun 9.

PMID:
21660972
18.

Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis.

Juo YY, Johnston FM, Zhang DY, Juo HH, Wang H, Pappou EP, Yu T, Easwaran H, Baylin S, van Engeland M, Ahuja N.

Ann Oncol. 2014 Dec;25(12):2314-27. doi: 10.1093/annonc/mdu149. Epub 2014 Apr 8. Review.

19.

Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.

Nagasaka T, Koi M, Kloor M, Gebert J, Vilkin A, Nishida N, Shin SK, Sasamoto H, Tanaka N, Matsubara N, Boland CR, Goel A.

Gastroenterology. 2008 Jun;134(7):1950-60, 1960.e1. doi: 10.1053/j.gastro.2008.02.094. Epub 2008 Mar 8.

20.

Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features.

Ang PW, Loh M, Liem N, Lim PL, Grieu F, Vaithilingam A, Platell C, Yong WP, Iacopetta B, Soong R.

BMC Cancer. 2010 May 21;10:227. doi: 10.1186/1471-2407-10-227.

Supplemental Content

Support Center